Monte Rosa Therapeutics (GLUE) Operating Expenses (2020 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at Monte Rosa Therapeutics was $210.58 million, up 29.2% year-over-year; for FY2025, it was $177.88 million, up 13.5% from FY2024.

• Annual Operating Expenses has increased for five consecutive years, with a five-year compound annual growth rate of 44.7% (FY2020 to FY2025).
• In prior years, Monte Rosa Therapeutics' Operating Expenses was $156.73 million in FY2024 (+9.4%), $143.31 million in FY2023 (+27.5%), $112.38 million in FY2022 (+54.2%) and $72.88 million in FY2021 (+160.2%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses in data going back to Q2 2020.
• On a year-over-year basis, Operating Expenses has increased in each of the last seven quarters, with growth averaging 21.4% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q3 2021, with growth of 211.1%; the weakest was Q3 2024, with a decline of 3.3%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $54.24 million (Q1 2026), $52.5 million (Q4 2025) and $45.74 million (Q3 2025).